Daily Stock Setups

Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com

Posted on: Thu, 29 Oct 2009 06:51:00 EDT

Symbols: TEVA, BIIB, GENZ, MBRX

Are you looking to increase your ETF knowledge?

DALLAS, Oct 29, 2009 (GlobeNewswire via COMTEX) --
TEVA | Quote | Chart | News | PowerRating -- StockPreacher.com announces an investment report featuring Metabasis Therapeutics (Nasdaq: MBRX | Quote | Chart | News | PowerRating). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/MBRX

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

Metabasis Therapeutics Inc. (MBRX) is a biopharmaceutical company focused on the discovery development of drugs. The Company's product pipeline includes product candidates and advanced discovery programs for the treatment of metabolic diseases such as diabetes and hyperlipidemia, which it refer to as its core assets, as well as product candidates and advanced discovery programs for the treatment of liver diseases such as hepatitis and primary liver cancer, which it refer to as its non-core assets.

Message Board Search for MBRX: http://www.boardcentral.com/boards/MBRX

In the report, the analyst notes:

"MBRX recently announced it has entered into a definitive merger agreement under which Ligand will acquire all of the outstanding shares of MBRX. Under the transaction, MBRX stockholders will receive a cash payment at the closing of the transaction of approximately $3.2 million, less MBRX's estimated net liabilities at closing and an amount to be deposited in the stockholders' representative's fund (Metabasis currently estimates the closing payment to be approximately $1.8 million in cash).

"MBRX announced on September 18, 2009, that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, notifying the Company that based upon the closing bid price of its common stock for the last 30 consecutive business days, the Company did not maintain a minimum closing bid price of $1.00 per share or more that is required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until March 15, 2010, in which to regain compliance."

To read the entire report visit: http://www.stockpreacher.com/n/SAY

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: StockPreacher

CONTACT:  StockPreacher.com
Jeff Bishop
(469)-252-3505
press@beaconequity.com

For full details on Teva Pharm Ind (TEVA) TEVA. Teva Pharm Ind (TEVA) has Short Term PowerRatings at TradingMarkets. Details on Teva Pharm Ind (TEVA) Short Term PowerRatings is available at This Link.

For full details on Biogen Idec Inc (BIIB) BIIB. Biogen Idec Inc (BIIB) has Short Term PowerRatings at TradingMarkets. Details on Biogen Idec Inc (BIIB) Short Term PowerRatings is available at This Link.

For full details on Genzyme Corporation (GENZ) GENZ. Genzyme Corporation (GENZ) has Short Term PowerRatings at TradingMarkets. Details on Genzyme Corporation (GENZ) Short Term PowerRatings is available at This Link.

For full details on Metabasis Therapeutics Inc (MBRX) MBRX. Metabasis Therapeutics Inc (MBRX) has Short Term PowerRatings at TradingMarkets. Details on Metabasis Therapeutics Inc (MBRX) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.